Novartis

Novartis halts malaria drug trial against COVID-19 amid participant shortfall | 6/20/2020

Novartis halts malaria drug trial against COVID-19 amid participant shortfall / KMJO 104.7 Duke FM June 19, 2020 04:17 pm By John Miller ZURICH (Reuters) - Swiss drugmaker Novartis is halting its trial of malaria drug hydroxychloroquine (HCQ) against COVID-19 after struggling to find participants, it said on Friday, as data emerged from other studies raising doubts about its efficacy. Novartis ‘ trial began in April and sought to test the …

Novartis stops hydroxychloroquine clinical trial | 6/20/2020

Novartis (NYSE: NVS ) says it is discontinuing its clinical trial of hydroxychloroquine as a treatment for COVID-19 patients after struggling to find participants. The company started the trial in April and wanted to test the drug in 440 hospitalized patients, but enrollment was so slow that the clinical team would have been unlikely to collect meaningful data in a reasonable timeframe. Novartis ’ move follows this week’s U.S. Food and …

Follow Novartis:    

Peapack Gladstone Financial Corp Increases Stock Holdings in Novartis AG (NYSE:NVS) | 6/20/2020

Peapack Gladstone Financial Corp boosted its stake in Novartis AG (NYSE:NVS) by 63.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 88,564 shares of the company’s stock after buying an additional 34,352 shares during the quarter. Peapack Gladstone Financial Corp’s holdings in Novartis were worth $7,302,000 as of its most recent SEC filing. A number of other large …

Global Immuno oncology Therapy Market is Expected to Grow at Moderate Pace by 2027 Post COVID 19 Pandemic, Latest Market Research Report by Cognitive Market Research Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Roche – Bandera County Courier | 6/20/2020

… Copy form the webstie: https://www.cognitivemarketresearch.com/electronics-%26-electrical/immuno-oncology-therapy-market-report The major players profiled in this report include: Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Roche, GlaxoSmithKline, Janssen Biotech, Merck, Novartis , Pfizer, Sanofi, Spectrum Pharmaceuticals, Takeda Market segment by type can be split into: Monoclonal Antibodies, Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines Market segment by the application can be split into: Hospitals, Ambulatory …

Global and Country Specific Immuno Oncology Market Report 2020 Forecast, Opportunities and Strategies To 2027: COVID 19 Impact and Recovery Top Key Players Amgen Inc, AstraZeneca Plc, Bristol Myers Squibb, Celgene Corporation, Eli Lilly and Company – Bandera County Courier | 6/20/2020

… analysis: Hospitals, Pharmacies, Online Pharmacies Major Market Players with an in-depth analysis: Amgen Inc, AstraZeneca Plc, Bristol Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co., Hoffmann La Roche AG, Johnson & Johnson, Novartis International AG, AbbVie, Pfizer Inc., Sanofi S.A., EMD Serono, Gilead Sciences Inc., Prometheus Therapeutics & Diagnostics, Aduro BioTech, Galena Biopharma, Bavarian Nordic, Celldex Therapeutics, ImmunoCellular Therapeutics, Incyte The research is presented in such a way that …

Public-Private Partnership To Improve The Lives Of People With Sickle Cell Disease | 6/20/2020

… current standard of care, in 11 treatment centers across Ghana • The partnership, launched in November 2019, is a collaboration between the Government of Ghana, the Sickle Cell Foundation of Ghana and global medicines company Novartis • Approximately 15,000 babies are born with sickle cell disease every year in Ghana Accra, June 19, 2020 – Today, on World Sickle Cell Day, the Sickle Cell Foundation of Ghana reports on progress made to date …

Royal Bank of Canada Decreases Stock Position in Novartis AG (NYSE:NVS) | 6/20/2020

Royal Bank of Canada cut its holdings in Novartis AG (NYSE:NVS) by 1.0% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,488,808 shares of the company’s stock after selling 15,091 shares during the period. Royal Bank of Canada owned about 0.07% of Novartis worth $122,752,000 as of its most recent SEC filing. Several other institutional investors have …

Assessment of COVID-19’s Effect on Non-Tumorous Skin Diseases Therapeutics Market 2020-2024 | Misdiagnosis of Skin Diseases to Augment Growth | Technavio | Business Wire | 6/20/2020

… Sample Report The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. AbbVie Inc., Amgen Inc., Bausch Health Companies Inc., Eli Lilly and Co., Galderma Laboratories LP, Johnson & Johnson, Novartis AG, Pfizer Inc., Sanofi, and Sun Pharmaceutical Industries Ltd. are some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast …

Eye Health Supplements Market Size, Share, Drivers and Growth Opportunity Analysis Report, 2019-2026 - Jewish Life News | 6/20/2020

… also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the eye health supplements market include Pfizer Inc., Novartis AG, Baush Health, Amway Corp., Vitabiotics Ltd., Alliance Pharma, The Nature’s Bounty Co. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities …

Novartis discontinues hydroxychloroquine clinical trial based on slow enrollment, remains committed to pandemic research efforts | 6/20/2020

Study discontinued due to feasibility of recruitment; no safety issues have been reported or efficacy conclusions made Novartis remains committed to ongoing research and development for COVID-19 Supply of hydroxychloroquine (HCQ) from Novartis will continue for clinical trials and upon government requests worldwide Basel, June 19, 2020 — Novartis has made the decision to stop and discontinue its sponsored HCQ clinical trial for COVID-19 due to acute enrollment challenges …

Local officials hit roadblocks on the way to enacting measures to curb coronavirus spikes - CNN | 6/20/2020

… cases of any in the state with a total of 2,206 cases. Uncertainty in the awaited treatments and vaccines Researchers are racing to get treatments and vaccines approved. But one clinical trial has ended. Novartis , one of the makers of hydroxychloroquine, announced Friday it was stopping its clinical trial in the US of the drug in coronavirus patients. The FDA revoked emergency authorization for the drug to be distributed to …

Small Cell Lung Cancer Therapeutics Market 2020 Is Rapidly Growing with Huge Application Scope & Opportunities By 2027 | Sanofi, Bristol-Myers Squibb, GlaxoSmithKline, Menarini, Ziopharm Oncology, Merck, Novartis, AstraZeneca | 6/20/2020

Sunny Denis June 20, 2020 The global analysis of Small Cell Lung Cancer Therapeutics Small Cell Lung Cancer Therapeutics //www.researchnreports.com/request_sample.php?id=687333 Major Key Players are as follows: Sanofi, Bristol-Myers Squibb, GlaxoSmithKline, Menarini, Ziopharm Oncology, Merck, Novartis, AstraZeneca, Takeda Pharmaceutical, Teva Pharmaceutical, Eli Lilly, Mylan, Sun Pharmaceuticals Industries, Amgen, Ono Pharmaceutical, Shanghai Jinhe Bio-Technology etc. The global Small Cell Lung Cancer Therapeutics Small Cell Lung Cancer …

Parkinson Disease Therapeutics Market 2020 Is Rapidly Growing with Huge Application Scope & Opportunities By 2027 |: AbbVie Inc., Novartis AG, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., UCB Inc, STADA Arzneimittel AG | 6/20/2020

Sunny Denis June 20, 2020 The global analysis of Parkinson Disease Therapeutics Parkinson Disease Therapeutics //www.researchnreports.com/request_sample.php?id=687325 Major Key Players are as follows: AbbVie Inc., Novartis AG, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., UCB Inc, STADA Arzneimittel AG, GlaxoSmithKline plc, Valeant Pharmaceuticals International, Inc., Merck & Co., Inc., and Impax Laboratories Inc. etc. The global Parkinson Disease Therapeutics Parkinson Disease Therapeutics market in the forecasted …

Incredible Growth of Post-Traumatic Stress Disorder Therapeutics Market Demand, Segmentation, Recent Trends, Strategies, Demand, Top Players and Business Outlook To 2027|Pfizer, Inc., GlaxoSmithKline plc, Otsuka Pharmaceutical Co., Ltd, Novartis AG | 6/20/2020

… business prospects. Request Sample Copy of this [email protected]: https://www.researchnreports.com/request_sample.php?id=778305 Some of the key players of Post-Traumatic Stress Disorder Therapeutics Market: Pfizer, Inc., GlaxoSmithKline plc, Otsuka Pharmaceutical Co., Ltd, Novartis AG, AstraZeneca Plc, Azevan Pharmaceuticals, Inc., Bionomics Ltd., Tonix Pharmaceuticals Holding Corp., Apotex, Inc. The global Post-Traumatic Stress Disorder Therapeutics market report also indicates a narrowed decisive summary of the global market. Along with …

Latest Report on Purpura Therapy Drugs Market by Growth, Demand & Opportunities & Forecast To 2027 | Bristol-Myers Squibb Company, Pfizer Inc, GlaxoSmithKline Plc, Novartis AG, Hovione | 6/20/2020

… understanding of this market. Get Sample Copy of this Report @ https://www.researchnreports.com/request_sample.php?id=790722 Some of the key players of Purpura Therapy Drugs Market: Bristol-Myers Squibb Company, Pfizer Inc, GlaxoSmithKline Plc, Novartis AG, Hovione, Sanofi Winthrop Industrie S.A., Hoffman-L Roche, Amgen Inc, Grifols Biologicals Inc, Ablynx NV, Biogen Inc, KM Biologics The Purpura Therapy Drugs Market research report offers an in-depth analysis of the market …

Progressive Report on Valley Fever Treatment Market by Growth, Demand & Opportunities & Forecast To 2027| Novartis, Pfizer, GlaxoSmithKline, Johnson & Johnson, Galderma, Bristol Meyer Squibb | 6/20/2020

Sunny Denis June 20, 2020 Valley Fever Treatment Market Analysis to 2027 is a specialized and in-depth study of the industry with a focus on the market trend. The research report on Valley Fever Treatment Market provides comprehensive analysis on market status and development pattern, including types, applications, rising technology and region. Valley Fever Treatment Market report covers the present and past market scenarios, market development patterns, and is …

Pediatric Antibiotics Market Research Report 2020 with COVID-19 Pandemic PESTEL Analysis, Growth Rate, New Trend Analysis Forecast to 2027| Johnson & Johnson, Astellas Pharma, Inc., Pfizer Inc., Novartis AG | 6/20/2020

… by key players. Sample Report with Latest Industry Trends : https://www.qyreports.com/request-sample/?report-id=226721 Top Manufacturers operated in the Global Pediatric Antibiotics Market such as Johnson & Johnson, Astellas Pharma, Inc., Pfizer Inc., Novartis AG, Bayer HealthCare AG, Bristol-Myers Squibb Co., Abbott Laboratories, Daiichi Sankyo Company, Ltd., GlaxoSmithKline Plc., and others. This report focuses on the Pediatric Antibiotics Market outlook, future outlook, growth opportunities and core and core …

Swiss Firm Novartis Stops Hydroxychloroquine Trial For COVID-19 Treatment | 6/20/2020

Swiss pharmaceuticals giant Novartis has decided to halt a clinical trial of hydroxychloroquine as a treatment for COVID-19, citing problems in recruiting enough patients for the study of the controversial drug. “Novartis has made the decision to stop and discontinue its sponsored HCQ clinical trial for COVID-19 due to acute enrolment challenges that have made trial completion infeasible,” the company said in a statement late Friday. This problem …

Post-Traumatic Stress Disorder Therapeutics Market Demand To 2027 | Pfizer, Inc., GlaxoSmithKline plc, Otsuka Pharmaceutical Co., Ltd, Novartis AG | 6/20/2020

… business prospects. Request Sample Copy of this [email protected]: https://www.researchnreports.com/request_sample.php?id=778305 Some of the key players of Post-Traumatic Stress Disorder Therapeutics Market: Pfizer, Inc., GlaxoSmithKline plc, Otsuka Pharmaceutical Co., Ltd, Novartis AG, AstraZeneca Plc, Azevan Pharmaceuticals, Inc., Bionomics Ltd., Tonix Pharmaceuticals Holding Corp., Apotex, Inc. The global Post-Traumatic Stress Disorder Therapeutics market report also indicates a narrowed decisive summary of the global market. Along with …

Swiss giant Novartis halts COVID-19 hydroxychloroquine study | 6/20/2020

Swiss pharmaceuticals giant Novartis has decided to halt a clinical trial of hydroxychloroquine as a treatment for COVID-19, citing problems in recruiting enough patients for the study of the controversial drug. “Novartis has made the decision to stop and discontinue its sponsored HCQ clinical trial for COVID-19 due to acute enrolment challenges that have made trial completion infeasible,” the company said in a statement late Friday. This problem …

Pulmonary Hypertension Drugs Market To 2027: GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc., Abbott Laboratories, Boehringer Ingelheim GmbH | 6/20/2020

… key growth strategies adopted by key players. Sample Report with Latest Industry Trends : https://www.qyreports.com/request-sample/?report-id=117564 Top Manufacturers operated in the Global Pulmonary Hypertension Drugs Market such as GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc., Abbott Laboratories, Boehringer Ingelheim GmbH, AstraZeneca plc, Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., Vectura Group plc This report focuses on the Pulmonary Hypertension Drugs Market outlook, future outlook, growth …

Assessment of COVID-19’s Effect on Needle-Free Drug Delivery Devices Market 2020-2024 | Technological Advances in Needle-Free Drug Delivery Devices to Augment Growth | Technavio | Financial Buzz | 6/20/2020

… The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. 3M Co., Antares Pharma Inc., Becton, Dickinson and Co., Enesi Pharma Ltd., GlaxoSmithKline Plc, Inovio Pharmaceuticals Inc., Mylan NV, Novartis AG, PharmaJet Inc., and Valeritas Holdings Inc. are some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments …

Novartis halts hydroxychloroquine trial against COVID-19 - SKY4PAK | 6/20/2020

Home Health Novartis halts hydroxychloroquine trial against COVID-19 Novartis halts hydroxychloroquine trial against COVID-19 2:09 AM Health, Swiss drugmaker Novartis is halting its trial of malaria drug hydroxychloroquine (HCQ) against COVID-19 after struggling to find participants, it said on Friday, as data emerged from other studies raising doubts about its efficacy. Novartis ’ trial began in April and sought to test the drug in 440 hospitalized patients. But …

Tremendous growth in DNA Vaccines Market- Final Report will cover the impact analysis of COVID-19 on this industry, 2020-2025 | Sanofi Aventis, Pfizer Pharmaceuticals, Novartis AG, Merck | 6/20/2020

… trends, size, and shares along with the productivity of industries. Request A Exclusive Sample Copy of This DNA Vaccines Market report at Key Players in this DNA Vaccines Market are:– Sanofi Aventis, Pfizer Pharmaceuticals, Novartis AG, Merck & Co This report gives an extensively wide-ranging analysis of the market expansion drivers, factors regulating and avoiding market enlargement, existing business sector outlines, market association, market predictions for coming years. The Global …

Magnificent Approach on Drug addiction treatment Market- Final Report will cover the impact analysis of COVID-19 on this industry, 2020-2025 | Indivior, Pfizer, Alkermes, Novartis, Mylan, Cipla, Glenmark | 6/20/2020

… such as graphs, charts, tables as well as pictures. Request A Exclusive Sample Copy of This Drug addiction treatment Market report at Key Players in this Drug addiction treatment Market are:– Indivior, Pfizer, Alkermes, Novartis, Mylan, Cipla, Glenmark, Dr Different sales strategies have been elaborated to get a clear idea for getting global clients rapidly. It helps various industry experts, policymakers, business owners as well as various c level people …

American Society of Clinical Oncology

Novartis data at ASCO and EHA showcase bold approaches to reimagine cancer and blood disorders through multiple therapeutic platforms | 5/14/2020

EAST HANOVER, N.J. Data from more than 110 abstracts, including Novartis-sponsored and investigator-initiated trials, will be presented during the upcoming American Society of Clinical Oncology ASCO20 Virtual Scientific Program and the European Hematology Association EHA25 Virtual Congress. The ASCO and EHA meetings will be held May 29-31 , and June 11-14 , respectively. “We are living in a world of uncertainty, but cancer won’t wait. Now, more than ever, we …

CRISPR

ASCO: Off-the-shelf CAR-T pioneer Allogene shows early hints of efficacy in lymphoma | FierceBiotech | 5/14/2020

The two FDA-approved CAR-T treatments for blood cancers, Novartis’s Kymriah and Kite/Gilead’s Yescarta, have improved the prognosis for many patients, but they have one key drawback: They are made from patients’ own … off-the-shelf CAR-T treatments, including Precision BioSciences and CRISPR Therapeutics, both of which also have CD19-directed treatments for non-Hodgkin lymphoma in phase 1 trials. Analysts are expecting those companies to release …

Food and Drug Administration

Akcea Reports Financial Results and Highlights for First Quarter 2020 | 5/5/2020

… countries, and potential to file for approval in Brazil through PTC Therapeutics Refile WAYLIVRA ® (volanesorsen) in the U.S. with the Food and Drug Administration, or FDA, this year Initiate a Phase 3 study of AKCEA … in the first quarter of 2019 as a result of Novartis’ exercise of its option to license AKCEA-APO(a)-L Rx . Expenses Akcea’s operating expenses, net of the reimbursement due from Ionis through the …

CDC

J&J backs ‘Masking For A Friend’ campaign starring Hillary Clinton, TikTok influencers and more | FiercePharma | 5/4/2020

… PAN, and the pharma giant’s role is both financial and participatory. PAN’s more than two dozen member groups include the CDC Foundation, iHeartMedia, Evoke Kyne, Federation of American Scientists and ONE Campaign. “Masking For a … global health security threats and pandemic preparedness. RELATED: AbbVie, Pfizer, Novartis and more pledge millions in COVID-19 disaster relief “COVID-19 highlights for the world that despite a lot of concerns about pandemic preparedness …

Biosimilars

Edited Transcript of NOVN.VX earnings conference call or presentation 28-Apr-20 11:00am GMT | 5/2/2020

Q1 2020 Novartis AG Earnings Call Basel May 2, 2020 (Thomson StreetEvents) – Edited Transcript of Novartis AG earnings conference call or presentation Tuesday, April 28, 2020 at 11:00:00am GMT TEXT version of Transcript Corporate Participants … 11% in constant currency. This was driven by a strong biosimilars performance with 31% constant currency growth as well as excellent performance in Europe with 19% constant currency growth. Now with respect to the U.S …

Wolfe Research

Edited Transcript of NOVN.VX earnings conference call or presentation 28-Apr-20 11:00am GMT | 5/2/2020

Q1 2020 Novartis AG Earnings Call Basel May 2, 2020 (Thomson StreetEvents) – Edited Transcript of Novartis AG earnings conference call or presentation Tuesday, April 28, 2020 at 11:00:00am GMT TEXT version of Transcript Corporate Participants … LLC, Research Division - MD & Senior Research Analyst Timothy Minton Anderson Wolfe Research, LLC - MD of Equity Research Presentation Operator [1] Good morning, and good afternoon, and welcome to the Novartis Q1 2020 Results Release Conference …

Regenerative Medicine

Intellia Therapeutics Names David Lebwohl, M.D., Chief Medical Officer | 4/30/2020

regenerative medicine efforts using stem-cell-derived pancreatic islets to cure type I diabetes starting in November 2018. Semma was acquired by Vertex Pharmaceuticals Inc., in October 2019. Prior to his role at Semma, Dr. Lebwohl held numerous senior-level drug development leadership positions at the global healthcare company, Novartis Pharmaceuticals Inc. (Novartis), where most recently he was senior vice president and franchise global program head, CAR-T, Promacta and …

CAR-T

Intellia Therapeutics Names David Lebwohl, M.D., Chief Medical Officer | Globe Newswire | 4/30/2020

… has been at the helm of premier development organizations that launched breakthrough oncology therapies to patients, most notably the recent CAR-T therapy, Kymriah®, and the multi-indication blockbuster, Afinitor®. Under his leadership, we look … level drug development leadership positions at the global healthcare company, Novartis Pharmaceuticals Inc. (Novartis), where most recently he was senior vice president and franchise global program head, CAR-T, Promacta and SEG101 Global Program Teams …

Clinical Data

Novartis Cosentyx® gains fourth indication in EU with first-in-class approval in axial spondyloarthritis spectrum | 4/29/2020

April 29, 2020 01:15 ET Source: Novartis International AG Cosentyx ® is the first fully-human IL-17A inhibitor indicated for patients in Europe with non-radiographic axial spondyloarthritis (nr-axSpA), which forms part of the … development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and …

Big Pharma

Merck, slower than its peers, edges into COVID-19 fight | 4/28/2020

Almost all of Merck’s Big Pharma peers have either on their own or, increasingly, with a partner, geared up to fight the good fight against COVID-19. Up until this week Merck, however, has been conspicuously absent from this call; but, in its first-quarter report today, the pharma announced that it is, slowly, looking to join the battle. The Big Pharma, which reported its financials alongside Pfizer and Novartis

Clinical Research

Novartis’ cholesterol buster, new trial starts fall victim to pandemic: report | FierceBiotech | 4/28/2020

The COVID-19 pandemic has driven biopharmas left and right to hit pause on clinical trials, and Novartis is no exception. The Swiss pharma has stopped enrolling patients in a trial of its cholesterol fighter … maxed out the doses of other therapies. RELATED: FDA urges clinical researchers to go virtual in response to COVID-19 pandemic The company is turning to digital methods to manage patients and keep its trials …

Department of Health and Human Services

Cytosorbents Appoints Dr. Efthymios N. Deliargyris, M.D., As Chief Medical Officer | PR Newswire | 4/27/2020

… European Medical Director, based in Munich, Germany and Global Medical Lead - Acute Cardiovascular Care at The Medicines Company, acquired by Novartis AG this year. Most recently Dr. Deliargyris was Chief Medical Officer of PLx Pharma … nearly $29 million from DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM), the …

NIH

Cytosorbents Appoints Dr. Efthymios N. Deliargyris, M.D., As Chief Medical Officer | PR Newswire | 4/27/2020

… European Medical Director, based in Munich, Germany and Global Medical Lead - Acute Cardiovascular Care at The Medicines Company, acquired by Novartis AG this year. Most recently Dr. Deliargyris was Chief Medical Officer of PLx Pharma … of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM), the U.S. Army, U.S. Special Operations Command (USSOCOM), the U.S. Air Force …

National Institutes of Health

Cytosorbents Appoints Dr. Efthymios N. Deliargyris, M.D., As Chief Medical Officer | PR Newswire | 4/27/2020

… European Medical Director, based in Munich, Germany and Global Medical Lead - Acute Cardiovascular Care at The Medicines Company, acquired by Novartis AG this year. Most recently Dr. Deliargyris was Chief Medical Officer of PLx Pharma … Army, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM), the U.S. Army, U.S. Special Operations Command (USSOCOM …

American Association for Cancer Research

AACR: A look at next-gen CAR-T therapies for blood cancers | FierceBiotech | 4/27/2020

… working on those wrinkles, though, and some early data that sketch out possible solutions will be presented virtually at the American Association for Cancer Research (AACR) this week . The first set of data, featuring a … the antigen the CAR-T is designed to hunt down. Novartis’ CAR-T therapy, Kymriah, is already approved for this type of leukemia, but it only targets CD19. The study was small and geared toward …

AACR

AACR: A look at next-gen CAR-T therapies for blood cancers | FierceBiotech | 4/27/2020

… and some early data that sketch out possible solutions will be presented virtually at the American Association for Cancer Research (AACR) this week . The first set of data, featuring a CAR-T treatment made from … the antigen the CAR-T is designed to hunt down. Novartis’ CAR-T therapy, Kymriah, is already approved for this type of leukemia, but it only targets CD19. The study was small and geared toward …

McGill University

Incyte Appoints Christine Lennon as General Manager, Incyte Biosciences Canada | Business Wire | 4/24/2020

… prior to joining Incyte Christine was President and CEO of Epigene Therapeutics. Prior to that, she spent eight years with Novartis in a variety of roles including Commercial Head, Solid Tumors/Rare Disorders, Novartis Oncology … Québec Capital. Christine earned both her MBA and BSc from McGill University and earned her Institute of Corporate Directors designation (ICD.D) in 2020. About Incyte Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused …

Precision Medicine

FoRx Therapeutics AG Raises EUR 10 Million Seed Round and Becomes First Company to Develop a Pipeline of Drugs Targeting DNA Replication Stress for Cancer | PR Newswire | 4/22/2020

… today announced the closing of a EUR 10 million seed financing led by M Ventures (venture capital arm of Merck ), Novartis Venture Fund and Omega Funds. Pfizer Ventures, the venture capital arm of Pfizer Inc … to market in multiple therapeutic areas, including oncology, rare diseases, precision medicine and others. Please visit omegafunds.com for additional information. About Pfizer Ventures Pfizer Ventures (PV), the venture capital arm of Pfizer Inc. was founded …

Digital Health

Novartis acquires digital therapeutic using video games, 3D glasses to treat ‘lazy eye’ | 4/20/2020

Mergers & Acquisitions Novartis acquires digital therapeutic using video games, 3D glasses to treat ‘lazy eye’ Alongside the purchase, the pharma company announced upcoming collaborations with major video game publisher Ubisoft and McGill University. April 20 … With video game design practices increasingly finding their place among digital health and digital therapeutics products, it’s also noteworthy that this acquisition also builds a bridge between Novartis and one of the world’s largest video …

Digital Therapeutics

Novartis ventures again into digital therapeutics with ‘lazy eye’ video game buy and collabs with Ubisoft, McGill | FierceBiotech | 4/20/2020

Novartis is taking another stab at the digital therapeutics space by acquiring a small startup developing a video game treatment for lazy eye, also known as amblyopia. The Big Pharma said it will continue the work of Phoenix-based Amblyotech—and maintain its multiyear collaborations with global gaming studio Ubisoft and McGill University—to gather regulatory approvals and bring a series of games to the market. Affecting about 3% of …

Biotech

EuroBiotech Report—Witty joins WHO project, Arix cuts, Galapagos, Leo and Novartis | FierceBiotech | 4/16/2020

Welcome to the latest edition of our weekly EuroBiotech Report. We start this week at the World Health Organization, which turned to ex-GlaxoSmithKline CEO Andrew Witty for help advancing a vaccine against COVID-19 … Pharma licensed a midphase eczema drug for $40 million upfront. Novartis teamed up with cell therapy startup TScan Therapeutics. And more. — Nick Taylor 1. WHO tasks ex-GSK CEO Witty with hastening COVID-19 vaccine …

Clinical Operations

54gene Closes $15M Series A | PR Newswire | 4/14/2020

… Series A round of $15M , led by Adjuvant Capita l , a life sciences fund backed by the International Finance Corporation, Novartis, and the Bill & Melinda Gates Foundation. The round included participation from Raba Capital , V8 … bioinformatics and data science; Michael F. Murray MD, Director of Clinical Operations, Center for Genomic Health Professor Dept of Genetics, Yale School of Medicine , Manuel Rivas PhD , Assistant Professor at Stanford University , Greg Hinkle PhD …

Readmissions

Re: Biofourmis Acquires Clinical-Grade Wearable Biosensor Platform Biovoation AG | HIT Consultant | 4/11/2020

… an impressive list of more than 80 current and previous clients/partners—including major players such as Microsoft, IBM Research, Novartis, AstraZeneca, Cleveland Clinic, Mayo Clinic, Penn Medicine and Helios. – The cash + equity deal includes … managing chronic conditions before patients’ health worsens, potentially reducing hospital readmissions and decreasing the need for emergency department visits to reduce costs. “Biofourmis’ powerful and predictive AI-driven Biovitals® ecosystem is now complete with the …

Medicare

Trade group calls for government coverage of digital therapeutics amid pandemic | 4/8/2020

… connect patients with tips and coaching for diseases like diabetes. For the most part, they are not currently covered for Medicare or Medicaid patients, though some private Medicare Advantage plans and Medicaid managed care organizations … and others of which are established pharmaceutical giants, such as Novartis and Bayer. advertisement The Digital Therapeutics Alliance is asking the federal health department to use its special powers during a national emergency to grant …

Digital Therapeutics Alliance

Trade group calls for government coverage of digital therapeutics amid pandemic | STAT | 4/8/2020

… Digital Therapeutics Alliance, the group calling for broader coverage of such tools. The alliance includes 35 companies, some of which are startups and others of which are established pharmaceutical giants, such as Novartis and Bayer. advertisement The Digital Therapeutics Alliance is asking the federal health department to use its special powers during a national emergency to grant publicly insured Americans access to digital therapeutics. The organization does not yet know …

Gilead Sciences

The top 10 drug launches since 2017 | FiercePharma | 5/18/2020

Gilead Sciences and Novartis have suffered because of their high prices, complicated manufacturing process and competitive clinical trials stealing away commercial patients. Early sales of Tesaro’s Zejula and Clovis Oncology’s Rubraca paled compared to AstraZeneca’s first-to-market Lynparza, a combination of Lynparza’s head start and the two smaller firms’ limited commercial power. GlaxoSmithKline’s two-drug HIV combos face an uphill fight in persuading doctors to turn from tried-and …

Merck

Why Johnson & Johnson Looks Undervalued At $145 | 5/15/2020

Novartis is up 20%, Pfizer 30%, and Merck 17%. If we look at the returns since the beginning of the year, J&J has significantly outperformed with a 1% gain vs. a decline of 13% for the S&P 500. Why is that? The healthcare sector, in general, has remained resilient throughout the crisis, thus far. For J&J, it is working on a potential vaccine for COVID-19, and …

Pfizer

Why Johnson & Johnson Looks Undervalued At $145 | 5/15/2020

Novartis is up 20%, Pfizer 30%, and Merck 17%. If we look at the returns since the beginning of the year, J&J has significantly outperformed with a 1% gain vs. a decline of 13% for the S&P 500. Why is that? The healthcare sector, in general, has remained resilient throughout the crisis, thus far. For J&J, it is working on a potential vaccine for COVID-19, and …

Genentech

Sosei Heptares Operational Highlights and Consolidated Results for the First Quarter 2020 | 5/13/2020

… LABA/LAMA/ICS combination for asthma patients, in which Sosei Heptares has an economic interest. It is being developed by Novartis and currently under review in Europe , Japan and Canada , among other countries. Further scientific … the world’s leading pharmaceutical companies, including Allergan, AstraZeneca, Daiichi-Sankyo, Genentech (Roche), Novartis, Pfizer and Takeda; and with innovative biotechnology companies, including Kymab, MorphoSys and PeptiDream. Sosei Heptares is headquartered in Tokyo, Japan with R …

Bristol-Myers

Caribou Biosciences Appoints Cherry Thomas, MD as Senior Vice President of Clinical Development - Business Wire | 5/11/2020

Bristol-Myers Squibb, Novartis, GlaxoSmithKline, and Amgen. “I am thrilled to be joining Caribou at this significant time in its evolution,” said Dr. Thomas. “I’m excited to be working with a team at the forefront of advancing groundbreaking gene-edited cell therapies to benefit patients with significant medical need.” About Caribou Biosciences, Inc. Caribou is a leading company in CRISPR genome editing founded by pioneers of CRISPR biology. The company …

BeiGene

Caribou Biosciences Appoints Cherry Thomas, MD as Senior Vice President of Clinical Development - Business Wire | 5/11/2020

… BeiGene, Ltd. where she oversaw development programs aimed to evaluate an immuno-oncology combination therapy targeting solid tumors. She also held the role of Vice President of Clinical Development at Jounce Therapeutics where she managed the company’s early development program and guided clinical trial execution. In addition, Dr. Thomas held leadership clinical development and medical roles in oncology at Bristol-Myers Squibb, Novartis, GlaxoSmithKline, and Amgen. “I am thrilled to …

Biogen

Anti-Inflammatory Biologics Market to Reach USD 149.80 Billion by 2027; Ongoing Trials for Anti-Tumour Necrosis Factor (TNF) to Elevate Market Scope, states Fortune Business Insights™ | 5/11/2020

Key Companies Profiled are AbbVie Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Pfizer Inc., Novartis AG, UCB S.A., Eli Lilly and Company, Amgen Inc., Biogen, among others. May 11, 2020 05:43 ET Source: Fortune Business Insights Pune, May 11, 2020 (GLOBE NEWSWIRE) – The global anti-inflammatory biologics market size is expected to reach USD 149.80 billion by 2027 , exhibiting a CAGR of 11.0% during the …

AbbVie

Monoclonal Antibody Therapy Market to Rise at 14.0% CAGR till 2027; Growing Investment in Product R&D will Create Several Opportunities for Market Growth, says Fortune Business Insights™ | 5/11/2020

Key Companies Covered in the Monoclonal Antibody Therapy Market Research Report Are AbbVie Inc., Merck & Co., Inc., F.Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Daiichi Sankyo Company, Limited, Novartis AG, Alexion Pharmaceuticals, Inc., Amgen Inc. and other key market players. May 11, 2020 11:00 ET Source: Fortune Business Insights Pune, May 11, 2020 (GLOBE NEWSWIRE) – The global monoclonal antibodies therapy market size is projected to …

GlaxoSmithKline

Caribou Biosciences Appoints Cherry Thomas, MD as Senior Vice President of Clinical Development - Business Wire | 5/11/2020

… Novartis, GlaxoSmithKline, and Amgen. “I am thrilled to be joining Caribou at this significant time in its evolution,” said Dr. Thomas. “I’m excited to be working with a team at the forefront of advancing groundbreaking gene-edited cell therapies to benefit patients with significant medical need.” About Caribou Biosciences, Inc. Caribou is a leading company in CRISPR genome editing founded by pioneers of CRISPR biology. The company is developing an …

Bristol-Myers Squibb

Caribou Biosciences Appoints Cherry Thomas, MD as Senior Vice President of Clinical Development - Business Wire | 5/11/2020

… Bristol-Myers Squibb, Novartis, GlaxoSmithKline, and Amgen. “I am thrilled to be joining Caribou at this significant time in its evolution,” said Dr. Thomas. “I’m excited to be working with a team at the forefront of advancing groundbreaking gene-edited cell therapies to benefit patients with significant medical need.” About Caribou Biosciences, Inc. Caribou is a leading company in CRISPR genome editing founded by pioneers of CRISPR biology. The company …

Merck & Co

Monoclonal Antibody Therapy Market to Rise at 14.0% CAGR till 2027; Growing Investment in Product R&D will Create Several Opportunities for Market Growth, says Fortune Business Insights™ | 5/11/2020

Key Companies Covered in the Monoclonal Antibody Therapy Market Research Report Are AbbVie Inc., Merck & Co., Inc., F.Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Daiichi Sankyo Company, Limited, Novartis AG, Alexion Pharmaceuticals, Inc., Amgen Inc. and other key market players. May 11, 2020 11:00 ET Source: Fortune Business Insights Pune, May 11, 2020 (GLOBE NEWSWIRE) – The global monoclonal antibodies therapy market size is projected to …

Sandoz

Apotex admits to generic price fixing, agrees to pay $24M criminal fine | 5/8/2020

Novartis exec . The agency has also inked agreements with Heritage Pharmaceuticals and Rising Pharmaceuticals featuring fines of $7 million and $3 million, respectively. Novartis’ Sandoz in March agreed to pay $195 million in its agreement. Read more on …

Apotex

Apotex admits to generic price fixing, agrees to pay $24M criminal fine | 5/8/2020

Apotex admits to generic price fixing, agrees to pay $24M criminal fine by May 8, 2020 12:16pm Apotex agreed to pay a $24 million penalty for generic drug price fixing. (Getty Images) Even amid a … from two former executives of Heritage Pharmaceuticals, plus a former Novartis exec . The agency has also inked agreements with Heritage Pharmaceuticals and Rising Pharmaceuticals featuring fines of $7 million and $3 million, respectively. Novartis’ Sandoz …

Teva Pharmaceutical

Multiple Sclerosis Market: 2020 Drivers, Restraints, Drug Class, Diagnosis, End-Users, Distribution Channel, Industry SWOT Analysis and Company Profiles Opexa Therapeutics, Inc, Actelion Pharmaceuticals Ltd | 5/7/2020

Teva Pharmaceutical Industries Ltd, Sanofi, Novartis AG, Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Pfizer, Inc., Biogen, Bayer AG, Actelion Pharmaceuticals Ltd, GlaxoSmithKline plc., Opexa Therapeutics, Inc and others. Get Sample PDF Copy (including COVID-19 Impact Analysis, full TOC, Tables, and Figures) of Global Multiple Sclerosis Market Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-multiple-sclerosis-market Global multiple sclerosis market is expected to gain market growth …

Teva Pharmaceutical

Multiple Sclerosis Market: 2020 Drivers, Restraints, Drug Class, Diagnosis, End-Users, Distribution Channel, Industry SWOT Analysis and Company Profiles Opexa Therapeutics, Inc, Actelion Pharmaceuticals Ltd | 5/7/2020

Teva Pharmaceutical Industries Ltd, Sanofi, Novartis AG, Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Pfizer, Inc., Biogen, Bayer AG, Actelion Pharmaceuticals Ltd, GlaxoSmithKline plc., Opexa Therapeutics, Inc and others. Get Sample PDF Copy (including COVID-19 Impact Analysis, full TOC, Tables, and Figures) of Global Multiple Sclerosis Market Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-multiple-sclerosis-market Global multiple sclerosis market is expected to gain market growth …

Boehringer Ingelheim

Oxford Biomedica plc Preliminary results for the year ended 31 December 2019 | 5/6/2020

… Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 550 people. Further information is available at www.oxb.com CHAIRMAN’S STATEMENT Introduction The Group achieved strong revenue growth …

Seattle Genetics

Cancer Monoclonal Antibodies Industry, Forecast to 2025 - Data on Bevacizumab, Rituximab, Trastuzumab, Cetuximab, Panitumumab and Others | PR Newswire | 5/5/2020

Novartis AG, Pfizer Inc., Roche Holding AG, Seattle Genetics Inc., Spectrum Pharmaceuticals Inc., etc. Key Questions Answered How has the global cancer monoclonal antibodies market performed so far and how will it perform in the coming years? What are the key regional markets? What is the breakup of the market based on the antibody type? What is the breakup of the market based on the medication type? What is the …

Abbott Laboratories

Pharmaceutical Manufacturing Industry Review 2017-2019 and Forecast to 2027 - Impact Assessment of the COVID-19 Pandemic | 5/5/2020

… Novartis, Lupin, GlaxoSmithKline, Gilead Sciences, Eli Lily , Merck & Co., Cipla, Astra Zeneca, Amgen, Actavis and Abbott Laboratories. What the report offers: Market share assessments for the regional and country-level segments Strategic recommendations for the new entrants Covers Market data for the years 2017, 2018, 2019, 2023 and 2027 Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) Strategic recommendations in key business segments based on the market …

Novo Nordisk

Pharmaceutical Manufacturing Industry Review 2017-2019 and Forecast to 2027 - Impact Assessment of the COVID-19 Pandemic | 5/5/2020

… Novo Nordisk, Novartis, Lupin, GlaxoSmithKline, Gilead Sciences, Eli Lily , Merck & Co., Cipla, Astra Zeneca, Amgen, Actavis and Abbott Laboratories. What the report offers: Market share assessments for the regional and country-level segments Strategic recommendations for the new entrants Covers Market data for the years 2017, 2018, 2019, 2023 and 2027 Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) Strategic recommendations in key business segments based on …

CVS Health

5 Biotech Trends to Follow in 2020 | PR Newswire | 5/5/2020

NEW YORK , May 5, The stock crash of 2020 has produced a lot of losers. But it’s also forged some winners. Mentioned in today’s commentary includes: Amgen Inc. (NASDAQ: AMGN ), Gilead Sciences, Inc. (NASDAQ: GILD ), Novartis AG (NYSE: NVS ), CVS Health Corporation (NYSE: CVS ), Becton, Dickinson and Company (NYSE: BDX ). One of the industries that is most likely to benefit from the COVID-19 outbreak and profit in the long …

CVS

5 Biotech Trends to Follow in 2020 | PR Newswire | 5/5/2020

NEW YORK , May 5, The stock crash of 2020 has produced a lot of losers. But it’s also forged some winners. Mentioned in today’s commentary includes: Amgen Inc. (NASDAQ: AMGN ), Gilead Sciences, Inc. (NASDAQ: GILD ), Novartis AG (NYSE: NVS ), CVS Health Corporation (NYSE: CVS ), Becton, Dickinson and Company (NYSE: BDX ). One of the industries that is most likely to benefit from the COVID-19 outbreak and profit in the long …

Allergan

Sosei Heptares Notes That Enerzair® Breezhaler® (QVM149) has been Recommended for Approval in the European Union for Treating Uncontrolled Asthma | 5/1/2020

… TOKYO and LONDON , May 1, 2020 /PRNewswire/ – Sosei Group Corporation (“the Company”; TSE: 4565) notes that its strategic alliance partner Novartis (SWX: NOVN) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for … partnerships with some of the world’s leading pharmaceutical companies, including Allergan, AstraZeneca, Daiichi-Sankyo, Genentech (Roche), Novartis, Pfizer and Takeda; and with innovative biotechnology companies, including Kymab, MorphoSys and PeptiDream. Sosei Heptares is headquartered in …

Celgene

Amgen’s anti-inflammatory Otezla makes its foray into COVID-19 | 5/1/2020

… COVID-19—Amgen CEO Bob Bradway vowed the company would find new ways to make its $13.4 billion acquisition of Celgene’s psoriasis drug Otezla worth the investment. Now, COVID-19 is presenting one such opportunity … virus. They include Roche’s Actemra , Sanofi and Regeneron’s Kevzara and Novartis’ Ilaris . Cambrex Webinar Understanding the Importance of Crystallization Processes to Avoid Unnecessary Cost, Risk and Development Delays Wednesday, May 27, 2020 10am ET / 7am …

GE Healthcare

Key Insights into DNA Vaccine Market in Germany: Extensive Profiles and Recent Developments of Market Players | PR Newswire | 5/1/2020

… GE Healthcare, GlaxoSmithKline PLC., Inovio Pharmaceuticals Inc., Merck & Co., Novartis AG, Pfizer Inc., Roche Diagnostics GMBH and Sanofi Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups and technological advancements to stay competitive in the market.This report segments the German DNA Vaccine market by type, technology and …

Regeneron Pharmaceuticals

Diabetic Retinopathy Market by Type, Treatment, End-user and Region - Forecast to 2025 - ResearchAndMarkets.com | Business & Finance | heraldchronicle.com | 5/1/2020

Novartis AG, Regeneron Pharmaceuticals Inc., Sirnaomics Inc., etc. Key Questions Answered How has the global diabetic retinopathy market performed so far and how will it perform in the coming years? What are the key regional markets? What is the breakup of the market based on the type? What is the breakup of the market based on the treatment type? What is the breakup of the market based on the end …

Goldman Sachs

Edited Transcript of NOVN.VX earnings conference call or presentation 28-Apr-20 11:00am GMT | 5/3/2020

Q1 2020 Novartis AG Earnings Call Basel May 3, 2020 (Thomson StreetEvents) – Edited Transcript of Novartis AG earnings conference call or presentation Tuesday, April 28, 2020 at 11:00:00am GMT TEXT version of Transcript Corporate Participants … and Head of Healthcare Equity Research Kerry Holford Keyur Parekh Goldman Sachs Group Inc., Research Division - Equity Analyst Laura Sutcliffe UBS Investment Bank, Research Division - Equity Research Analyst Mark Douglas Purcell Morgan Stanley, Research Division …

Merrill Lynch

Edited Transcript of NOVN.VX earnings conference call or presentation 28-Apr-20 11:00am GMT | Yahoo News | 5/3/2020

Q1 2020 Novartis AG Earnings Call Basel May 3, 2020 (Thomson StreetEvents) – Edited Transcript of Novartis AG earnings conference call or presentation Tuesday, April 28, 2020 at 11:00:00am GMT TEXT version of Transcript Corporate Participants … Asset Research - Senior Equity Analyst Graham Glyn Charles Parry BofA Merrill Lynch, Research Division - MD and Head of Healthcare Equity Research Kerry Holford Keyur Parekh Goldman Sachs Group Inc., Research Division - Equity Analyst Laura Sutcliffe …

JP Morgan

Edited Transcript of NOVN.VX earnings conference call or presentation 28-Apr-20 11:00am GMT | Yahoo News | 5/3/2020

Q1 2020 Novartis AG Earnings Call Basel May 3, 2020 (Thomson StreetEvents) – Edited Transcript of Novartis AG earnings conference call or presentation Tuesday, April 28, 2020 at 11:00:00am GMT TEXT version of Transcript Corporate Participants … Research Division - Senior Equity Analyst & European Pharmaceuticals Analyst Richard Vosser JP Morgan Chase & Co, Research Division - Senior Analyst Seamus Christopher Fernandez Guggenheim Securities, LLC, Research Division - Senior Analyst of Global Pharmaceuticals Simon P. Baker Redburn …

Morgan Stanley

Edited Transcript of NOVN.VX earnings conference call or presentation 28-Apr-20 11:00am GMT | Yahoo News | 5/2/2020

Q1 2020 Novartis AG Earnings Call Basel May 2, 2020 (Thomson StreetEvents) – Edited Transcript of Novartis AG earnings conference call or presentation Tuesday, April 28, 2020 at 11:00:00am GMT TEXT version of Transcript Corporate Participants … Investment Bank, Research Division - Equity Research Analyst Mark Douglas Purcell Morgan Stanley, Research Division - Equity Analyst Matthew Weston Crédit Suisse AG, Research Division - MD and Co-Head of European Pharmaceutical Equity Research Peter James Welford …

Guggenheim Securities

Edited Transcript of NOVN.VX earnings conference call or presentation 28-Apr-20 11:00am GMT | Yahoo News | 5/2/2020

Q1 2020 Novartis AG Earnings Call Basel May 2, 2020 (Thomson StreetEvents) – Edited Transcript of Novartis AG earnings conference call or presentation Tuesday, April 28, 2020 at 11:00:00am GMT TEXT version of Transcript Corporate Participants … Morgan Chase & Co, Research Division - Senior Analyst Seamus Christopher Fernandez Guggenheim Securities, LLC, Research Division - Senior Analyst of Global Pharmaceuticals Simon P. Baker Redburn (Europe) Limited, Research Division - Head of Pharmaceutical Research Stephen Michael Scala …

Atlas Venture

Cadent Therapeutics Closes $15 Million Final Equity Tranche of Series B Financing | 4/29/2020

Atlas Venture and Chairman of the Board. The Series B financing was led by Cowen Healthcare Investments and Atlas Venture, with participation from Qiming Venture Partners, Access Industries, Clal Biotechnology Industries and Novartis Institutes for Biomedical Research. Due to the COVID-19 pandemic, Cadent will be delaying the initiation of the planned clinical trial of CAD-1883, the company’s lead movement disorder asset, in spinocerebellar ataxia, and focusing resources on …

8VC

Funding Roundup: Company creating ‘digital twins’ for clinical trials raises $12M - MedCity News | 4/25/2020

… developing a platform to populate control arms with “digital twins.” Unlearn closed a $12 million series A round led by 8VC. As part of the investment, 8VC Principal Francisco Gimenez will join the company’s board … board of directors. Other participating investors in the round include Novartis DRX, Y Combinator, and Baron Davis Enterprises. Clever Care Amount: $20 million Headquarters: Westminster, Calif. Clever Care Health Plan, a startup planning to launch …

HealthCare Ventures

Incyte Appoints Christine Lennon as General Manager, Incyte Biosciences Canada | Business Wire | 4/24/2020

… patients that need them.” A pharmaceutical executive with over 25 years of experience, prior to joining Incyte Christine was President and CEO of Epigene Therapeutics. Prior to that, she spent eight years with Novartis in a variety of roles including Commercial Head, Solid Tumors/Rare Disorders, Novartis Oncology Canada; GM of Oncology, Novartis Ireland; and Head of Policy, Market Access, Stakeholder Relations, Novartis Oncology Canada. Christine has also held leadership …

Menlo Ventures

‘LinkedIn for healthcare’ startup lands $13M backed by Menlo Ventures, Novartis | FierceHealthcare | 4/22/2020

A startup called H1 landed $12.9 million in a Series A funding round to scale up its platform that serves as a LinkedIn for the pharmaceutical and biotech industries. The company’s first institutional funding round was led by Menlo Ventures, a 44-year old venture capital firm, and was joined by Novartis DRX, Y Combinator, and Liquid 2 Ventures, a seed-stage fund led by former NFL quarterback Joe Montana …

Blackstone Group

CW Holt Advisory Comments On Alnylam Receiving $2 billion Backing From Blackstone For Gene-Silencing Initiatives | Business Wire | 4/15/2020

SEOUL, South Korea- South Korean wealth management company, CW Holt Advisory analysts have commented saying that on Monday, Blackstone Group Inc advised it would commit $2 billion U.S Dollars to Alnylam Pharmaceuticals Inc through an … The Medicines Co and was acquired earlier this year by Novartis AG. “Alnylam is entitled to collect up to 20% of royalties on the global sales of Inclisiran from Novartis. The company also announced they …

Biogen Idec

2020 Insights on the Worldwide Pharma, Biotech and Diagnostics Manufacturing and Supply Partnering Terms and Agreements | Globe Newswire | 4/14/2020

… Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.The report also includes numerous table and figures that illustrate the trends and activities in manufacturing and supply deal making since 2014. In addition, a comprehensive appendix is provided organized by manufacturing and supply company A-Z , stage of development, therapeutic target, technology …

KdT Ventures

54gene Closes $15M Series A | 4/14/2020

WASHINGTON , April 14, 54gene , the African genomics research, services, and development company has closed a Series A round of $15M , led by Adjuvant Capita l , a life sciences fund backed by the International Finance Corporation, Novartis, and the Bill & Melinda Gates Foundation. The round included participation from Raba Capital , V8 Capital , Ingressive Capital , and follow on investment from Y Combinator , Better Ventures , Fifty Years , KdT Ventures , Aera VC and Pioneer …

International Finance Corporation

54gene Closes $15M Series A | PR Newswire | 4/14/2020

WASHINGTON , April 14, 54gene , the African genomics research, services, and development company has closed a Series A round of $15M , led by Adjuvant Capita l , a life sciences fund backed by the International Finance Corporation, Novartis, and the Bill & Melinda Gates Foundation. The round included participation from Raba Capital , V8 Capital , Ingressive Capital , and follow on investment from Y Combinator , Better Ventures , Fifty Years , KdT Ventures , Aera VC and Pioneer …

SVB Leerink

Another Zolgensma delay is bad for Novartis in SMA but good for Biogen’s Spinraza: analyst | FiercePharma | 4/2/2020

Novartis has been working hard to expand the market for Zolgensma, its gene therapy to treat spinal muscular atrophy (SMA), by seeking approval for a version of the product that could be delivered by intrathecal … year—or possibly next year. That news prompted analysts at SVB Leerink to revise its predictions of when the first SMA patients would be able to receive Zolgensma IT. That will no longer happen in …

Bill & Melinda Gates Foundation

Big Pharma companies join forces for fightback against COVID-19 | FierceBiotech | 3/27/2020

Novartis and Pfizer are contributing to the joint response through actions including the sharing of proprietary compound libraries. With the SARS-CoV-2 coronavirus spreading quickly around the world, some of the companies best equipped to help mount a fightback against the pathogen have joined forces with the Bill & Melinda Gates Foundation. The companies held a conference call with leaders at the Gates Foundation earlier this month, leading 15 businesses …

Flagship Pioneering

Bristol Myers nabs M&A pro with $200B in deals under her belt to helm business development | FiercePharma | 3/18/2020

… Novartis’ former head of oncology development, Samit Hirawat, M.D. And CFO Charlie Bancroft headed for retirement to be replaced by Celgene CFO David Elkins. Biondi’s departure was a bit of a surprise, however. Initially, BMS appointed him to the 15-member management team of the combined company. But he chose instead to leave and join the biotech venture capital firm Flagship Pioneering. Bristol’s continued focus on looking outside its own …

Versant Ventures

EuroBiotech Report—LSP’s $600M fund, Versant’s Basel expansion, Numab round and Cell Medica | FierceBiotech | 3/12/2020

… plans to use the money to correct a perceived imbalance between the levels of breakthrough science and funding in Europe. Versant Ventures, a U.S.-based peer of LSP, has also identified Europe as a land … lead oncology drug ND021. Daniel Vasella, the former CEO of Novartis, was among the people to participate in the financing round. 4. Cell Medica rebrands as Kuur, raises cash for CAR-NKT trials Cell Medica …

New Enterprise Associates

Akouos nabs meaty $105M raise, adds VC and biotech veterans to board | FierceBiotech | 3/4/2020

Boston-based hearing loss gene therapy biotech Akouos has grabbed a $105 million series B funding round. A whole host of big names waded into this financing, including the likes of 5AM Ventures, New Enterprise Associates, Novartis Venture Fund and Partners Innovation Fund (which also was an early investor in Akouos’ $50 million series A) as well as new participants Cowen Healthcare Investments, Polaris and Pivotal bioVenture Partners, which led …

Pivotal bioVenture Partners

Akouos nabs meaty $105M raise, adds VC and biotech veterans to board | FierceBiotech | 3/4/2020

Boston-based hearing loss gene therapy biotech Akouos has grabbed a $105 million series B funding round. A whole host of big names waded into this financing, including the likes of 5AM Ventures, New Enterprise Associates, Novartis Venture Fund and Partners Innovation Fund (which also was an early investor in Akouos’ $50 million series A) as well as new participants Cowen Healthcare Investments, Polaris and Pivotal bioVenture Partners, which led …

Innovation Fund

Akouos nabs meaty $105M raise, adds VC and biotech veterans to board | FierceBiotech | 3/4/2020

Boston-based hearing loss gene therapy biotech Akouos has grabbed a $105 million series B funding round. A whole host of big names waded into this financing, including the likes of 5AM Ventures, New Enterprise Associates, Novartis Venture Fund and Partners Innovation Fund (which also was an early investor in Akouos’ $50 million series A) as well as new participants Cowen Healthcare Investments, Polaris and Pivotal bioVenture Partners, which led …

Redmile Group

Targeting deadly lung-scarring disease, Peninsula biotech snares $100M crossover round | The Business Journals | 3/3/2020

… that builds up and blocks the lungs and bile ducts, Pliant Therapeutics Inc. raised a $100 million round from giant Novartis AG and a band of crossover investors that will launch its marquee drug through … drug maker Novartis AG, but was joined by crossover investors Redmile Group, Farallon Capital Management, Cormorant Asset Management, Surveyor Capital and Logos Capital, hinting that Pliant is lining up an initial public offering. Existing investors …

MPM Capital

MPM gains first refusal on Dana-Farber tech, raises $100M fund | FierceBiotech | 2/26/2020

MPM Capital and Dana-Farber Cancer Institute have formed a venture philanthropy alliance, raising a $100 million investment fund and $26 million in donations to support early stage research. Dana-Farber and MPM have worked together in the past to create CoStim Pharmaceuticals, which was bought by Novartis, and the AbbVie-partnered Tizona Therapeutics. Those successes put MPM toward the top of the list of potential partners when Dana-Farber …

Access Industries

Cadent Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference | Business Wire | 2/19/2020

Novartis to develop a negative allosteric modulator, now in Phase 2 for the treatment of treatment resistant depression. Investors include Atlas Venture, Cowen Healthcare Investments, Qiming Venture Partners, Access Industries, Clal Biotechnology Industries, Novartis Corporate and Slater Technology Fund. For more information, please visit cadenttx.com . View source version on businesswire.com : https://www.businesswire.com/news/home/20200219005865/en/ CONTACT: Investors …

Stryker

Innisfree M&A Incorporated Receives Top 2019 Proxy Solicitor Rankings in M&A and Activism | Business Wire | 2/13/2020

Novartis in its tender for The Medicines Company, Sanofi in its tender offer for Synthorx, Sotheby’s in its merger with BidFair, Stryker in its tender offer for Wright Medical Group, and Versum Materials Inc. in its acquisition by Merck KGaA. In addition, Innisfree has been named the top Global Proxy Solicitor for companies by the Bloomberg Global Activism Review and the top issuer proxy solicitor by Activist Insight and Refinitiv …

Silicon Valley Bank

Mereo BioPharma Enters into a $5 Million Convertible Equity Financing with Novartis and Announces a Securities Purchase Agreement with Aspire Capital Fund, LLC for up to $28 Million | Globe Newswire | 2/10/2020

… biopharmaceutical company focused on rare diseases, today announced that it has entered into a $5 million convertible equity financing with Novartis Pharma (AG) (“Novartis”) and concurrently entered into a Securities Purchase Agreement to issue up … Note will be subordinate to Mereo’s outstanding loan agreement with Silicon Valley Bank and Kreos Capital. About the Aspire Capital Securities Purchase Agreement Under the terms of the Securities Purchase Agreement (the “Agreement”), Aspire Capital …

Meridian Health

2020 Donate Life Transplant Games Rescheduled To July 2021 At New Jersey Meadowlands | 4/23/2020

… Meridian Health, RWJ Barnabas, Novartis Pharmaceuticals, American Dream, Meadowlands Live! Convention and Visitors Bureau, nearly all of the original programming will remain intact on the new dates,” continued Ryan. At the 2016 bid announcement, Joe Roth , President and CEO of NJ Sharing Network said, “The Transplant Games are the ultimate representation of what we stand for: courage, achievement, and triumph over adversity.” Now more than ever those words ring true …

Hackensack Meridian Health

2020 Donate Life Transplant Games Rescheduled To July 2021 At New Jersey Meadowlands | 4/23/2020

… Hackensack Meridian Health, RWJ Barnabas, Novartis Pharmaceuticals, American Dream, Meadowlands Live! Convention and Visitors Bureau, nearly all of the original programming will remain intact on the new dates,” continued Ryan. At the 2016 bid announcement, Joe Roth , President and CEO of NJ Sharing Network said, “The Transplant Games are the ultimate representation of what we stand for: courage, achievement, and triumph over adversity.” Now more than ever those words ring …

Hackensack Meridian

2020 Donate Life Transplant Games Rescheduled To July 2021 At New Jersey Meadowlands | 4/23/2020

Hackensack Meridian Health, RWJ Barnabas, Novartis Pharmaceuticals, American Dream, Meadowlands Live! Convention and Visitors Bureau, nearly all of the original programming will remain intact on the new dates,” continued Ryan. At the 2016 bid announcement, Joe Roth , President and CEO of NJ Sharing Network said, “The Transplant Games are the ultimate representation of what we stand for: courage, achievement, and triumph over adversity.” Now more than ever those words ring …

Cleveland Clinic

Re: Biofourmis Acquires Clinical-Grade Wearable Biosensor Platform Biovoation AG | HIT Consultant | 4/11/2020

Biofourmis acquires Zürich, Switzerland-based Biovotion AG, a leading developer of a cutting-edge clinical-grade wearable biosensor platform. – The Biovotion AG deal comes with 60 global patents covering much of the existing wearables tech for the arm and hand, as well as an impressive list of more than 80 current and previous clients/partners—including major players such as Microsoft, IBM Research, Novartis, AstraZeneca, Cleveland Clinic, Mayo Clinic, Penn …

Penn Medicine

Re: Biofourmis Acquires Clinical-Grade Wearable Biosensor Platform Biovoation AG | HIT Consultant | 4/11/2020

Biofourmis acquires Zürich, Switzerland-based Biovotion AG, a leading developer of a cutting-edge clinical-grade wearable biosensor platform. – The Biovotion AG deal comes with 60 global patents covering much of the existing wearables tech for the arm and hand, as well as an impressive list of more than 80 current and previous clients/partners—including major players such as Microsoft, IBM Research, Novartis, AstraZeneca, Cleveland Clinic, Mayo Clinic, Penn …

Mayo Clinic

ACC: New owner Novartis presents pooled inclisiran data cutting LDL cholesterol by half | FierceBiotech | 3/28/2020

A new analysis of the cholesterol-lowering inclisiran could add some juice to the PCSK9 drug—which Novartis picked up in its $9.7 billion purchase of The Medicines Company last year—showing it was able … phase 3 studies, and a professor of medicine at the Mayo Clinic. RELATED: The 10 most-anticipated drug launches of 2020 Inclisiran Inclisiran consists of double-stranded, small interfering RNA that hinders the expression of …

Baylor College of Medicine

EuroBiotech Report—LSP’s $600M fund, Versant’s Basel expansion, Numab round and Cell Medica | FierceBiotech | 3/12/2020

… Novartis, was among the people to participate in the financing round. 4. Cell Medica rebrands as Kuur, raises cash for CAR-NKT trials Cell Medica has rebranded as Kuur Therapeutics, pulling in fresh funds from IP Group, Baylor College of Medicine and Schroder Adveq along the way. Kuur will use the money to fund phase 1 trials of autologous and allogeneic CAR natural killer T-cell (CAR-NKT) therapies. And …

MD Anderson Cancer Center

Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials | PR Newswire | 3/10/2020

… of the declaration of Helsinki 2008. Ethical approval has been granted from Institutional Review Boards at Fox Chase Cancer Center, MD Anderson Cancer Center and H. Lee Moffitt Cancer Center (University of South Florida). All … N.V.: Research funding from Merck, Bayer. A.D.: Consulting fee from Novartis, Ipsen, Voluntis, Abbvie, Crinetics, Hutchison Pharma and Research funding from Novartis, Eisai, Ipsen, Hutchison Pharma. D.H.: Consulting fee from Lexicon, Ipsen, Advanced Accelarator Applications …

Harvard Medical School

What health insurance doesn’t cover | Fortune | 2/12/2020

… health care promotes economic inequality," Dr. Adam Gaffney, president of Physicians for a National Health Program and an instructor at Harvard Medical School, told ProPublica . Say your doctor sends you to the local hospital to … lab testing results alongside individualized counseling. ( MobiHealthNews ) \n INDICATIONS \n Novartis moves forward in the lung cancer space. Swiss pharma giant Novartis just got a boost in its quest to challenge rivals such as Merck …

Kaiser Permanente

Shifts in pharma’s 2020 digital health landscape | MobiHealthNews | 1/28/2020

… officer at Boston Children’s Hospital, Biogen’s VP of innovation and external partnerships, and VP of innovation and advanced technology at Kaiser Permanente. Follow Naomi on Twitter @NaomiFried. In 2019, a number of big pharma companies … announcement in the past six months was the decision from Novartis’ Sandoz to end its novel commercialization partnership with Pear Therapeutics. In Q3 2017, Pear garnered a lot of attention for receiving US FDA approval …

Memorial Sloan Kettering Cancer Center

MIAMI CANCER INSTITUTE ANNOUNCES LAUNCH OF INAUGURAL SUMMIT OF THE AMERICAS | Globe Newswire | 1/23/2020

… Source: Baptist Health South Florida photo-release MIAMI, Jan. 23, 2020 (GLOBE NEWSWIRE) – Some of the world’s leading experts from Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, MD Anderson Cancer Center, University of … tier biopharmaceutical and biotech organizations, Celgene, Genentech, Janssen, Sanofi, Jazz, Novartis, Atara, EUSA Pharma, Kite, Medgene, the symposium will provide a wealth of new information from every presentation. Attendees can expect many presentations that feature …

University of Texas MD Anderson Cancer Center

B cells and tertiary lymphoid structures promote immunotherapy response | Nature | 1/15/2020

University of Texas MD Anderson Cancer Center that covers methods to enhance immune checkpoint blockade responses by modulating the microbiome. J.A.W. reports compensation for speaker’s bureau and honoraria from Imedex, Dava Oncology, Omniprex, Illumina, Gilead, PeerView, Physician Education Resource, MedImmune and Bristol-Myers Squibb. J.A.W. serves as a consultant/advisory board member for Roche/Genentech, Novartis, AstraZeneca, GlaxoSmithKline, Bristol-Myers Squibb, Merck, Biothera Pharmaceuticals and Microbiome DX. J.A.W. also receives …

UPMC

Xealth is Honored in Built In Seattle’s Prestigious Best Places to Work List in 2020 | PR Newswire | 1/13/2020

… Novartis, Philips, and ResMed as well as Providence Ventures, UPMC and the Froedtert and Medical College of Wisconsin Health Network. For more information, visit www.xealth.com or follow us on LinkedIn or Twitter . About Built In Working in tech is a way of life. Built In helps people live it with purpose. Across the most vibrant tech hubs in the US, Built In helps tech professionals stay on top of tech …

MemorialCare

Xealth is Honored in Built In Seattle’s Prestigious Best Places to Work List in 2020 | PR Newswire | 1/13/2020

MemorialCare Innovation Fund, McKesson Ventures, Novartis, Philips, and ResMed as well as Providence Ventures, UPMC and the Froedtert and Medical College of Wisconsin Health Network. For more information, visit www.xealth.com or follow us on LinkedIn or Twitter . About Built In Working in tech is a way of life. Built In helps people live it with purpose. Across the most vibrant tech hubs in the US, Built In helps tech professionals …

Massachusetts General Hospital

Cellectar Appoints Dr. Igor Grachev as Chief Medical Officer | Globe Newswire | 1/7/2020

… Novartis, GSK, Merck, Schering Plough, Sanofi-Aventis, and BioClinica. Dr. Grachev is a former Assistant Professor of Radiology at SUNY Upstate Medical University and as a Fellow in Radiology at Massachusetts General Hospital, Harvard Medical School. Dr. Grachev is well-published in the field of radiopharmaceuticals, drug development and innovative clinical trials. He also possesses extensive oncology radiopharmaceutical and diagnostic development experience with GE Healthcare where he had global responsibility …

Tufts Medical Center

Crisis Looms in Antibiotics as Drugmakers Go Bankrupt | Yahoo News | 12/25/2019

… deadly, drug-resistant bacteria. Antibiotic startups like Achaogen and Aradigm have gone belly up in recent months, pharmaceutical behemoths like Novartis and Allergan have abandoned the sector and many of the remaining American antibiotic companies … everyone,” said Dr. Helen Boucher, an infectious disease specialist at Tufts Medical Center and a member of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria. The problem is straightforward: The companies that have invested …

Memorial Sloan Kettering

Kite Pharma, Juno duke it out in court over megamillion-dollar CAR-T patent | FiercePharma | 12/12/2019

… technology invented and patented by scientists at Sloan Kettering. Juno exclusively licensed the ‘190 patent from Sloan Kettering and the Memorial Sloan Kettering Cancer Center in November 2013, the lawsuit claims. Before that license deal … didn’t immediately respond to requests for comment. RELATED: Move over, Novartis: Kite and Gilead break into CAR-T market with early axi-cel nod Further, Kite tried to challenge the ‘190 patent with an inter …

UW Medicine

$42 Million Organ-On-Chip Market is Finding Applications in Space | PR Newswire | 12/9/2019

UW Medicine researchers, in collaboration with Novartis, a Seattle -based OOC company, are developing a “kidney-on-a-chip” model to be used in space for drug, toxin and environmental exposures, and to understand how microgravity and other factors affect kidney health. This project is funded by NCATS with $3 million grant, and CASIS will contribute the space flight, time in station, and space station crew costs, for an in …

National Jewish Health

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… discusses activities of the big pharmaceutical companies that are investing in biomarkers development through, for example, collaborations with CROs: • Pfizer • Novartis • Roche Diagnostics • Ventana Medical Systems • Merck & Co. • Sanofi • GSK • Abbott Laboratories • AstraZeneca • Key questions … Infectious Diseases (NIAID) [US] National Institute on Aging ( NIA) [US] National Jewish Health [US] Newcastle University [UK] NIH (National Institute of Health) Oslo University Hospital Pharmaceutical Research and Manufacturers of America (PhRMA) Pharmaceuticals and Medical …

University of Texas Southwestern Medical Center

Pulmonary artery pressure measurement via sensors may improve outcomes in HF | 12/3/2019

… the EMPULSE study, has received research grants from Vifor Pharma and has other financial relationships with Abbott, Boehringer Ingelheim and Novartis. Please see the abstracts for all other authors’ relevant financial disclosures. Christiane Angermann PHILADELPHIA … Drazner, MD Medical Director, LVAD and Cardiac Transplantation Program Professor University of Texas Southwestern Medical Center, Dallas Disclosures: Drazner reports no relevant financial disclosures …

Beth Israel Deaconess Medical Center

Visiongain Report Looks at Opportunities within the $1.8bn Acute Myeloid Leukaemia Market | PR Newswire | 11/28/2019

… major players in the acute myeloid leukaemia market: • Bristol-Myers Squibb Company • Celgene • Clavis Pharma ASA • Daiichi Sankyo • Eisai • GSK • Novartis • Roche • Sunesis Pharmaceuticals • Teva • This report discusses factors that drive and restrain the acute … and White Research Institute Benaroya Research Institute at Virginia Mason Beth Israel Deaconess Medical Center Breslin Cancer Center Center for Blood Disorders and Stem Cell Transplantation Charles A. Sammons Cancer Center Columbia University Medical Dana …

The University of Texas MD Anderson Cancer Center

Visiongain Report Looks at Opportunities within the $1.8bn Acute Myeloid Leukaemia Market | PR Newswire | 11/28/2019

… major players in the acute myeloid leukaemia market: • Bristol-Myers Squibb Company • Celgene • Clavis Pharma ASA • Daiichi Sankyo • Eisai • GSK • Novartis • Roche • Sunesis Pharmaceuticals • Teva • This report discusses factors that drive and restrain the acute … Center The University of Hong Kong The University of Iowa The University of Texas MD Anderson Cancer Center Thomas Jefferson University U.S. Food and Drug Administration (FDA) UCLA Medical Center, Division of Hematology/Oncology University …

UT Southwestern Medical Center

Global RNAi Therapeutics Market 2019-2030: Focus on siRNA, miRNA, shRNA and DNA | PR Newswire | 11/27/2019

… Translational Sciences (NCATS), National Institutes of Health National Institutes of Health National Health and Medical Research Council (NHMRC) Nitto Denko Novartis Novozymes Oligoengine OliX Pharmaceuticals Omnia Biologics OnCore Biopharma OriGene Technologies Oxford Finance Partner Fund … Pennsylvania University of Texas University of Virginia School of Medicine UT Southwestern Medical Center Value Measured Investment Vector Biolabs Vir Biotechnology ViThera Laboratories Weston Biotechnology WTT Investment YuYu Pharma Yuexiu New Industrial Investment Yuhan ZonMw …

Northwell Health

MYRX365 Announces Physician Advisory Board & Joins StartUp Health | PRWeb | 11/26/2019

… therapies and opioid alternatives to pain management. The advisory board includes the following physicians: Ram Raju, MD Surgery SVP of Northwell Health and former CEO of NYC Health + Hospitals Armand Dorian, MD Emergency Medicine Chief … Feld, GuideWell, Jason Finger, Jerry Levin, Kaiser Permanente Ventures, Masimo, Novartis, Otsuka, Ping An Group, and SeventySix Capital, StartUp Health has the world’s largest digital health portfolio with more than 290 companies spanning six continents …

University of Pittsburgh Medical Center

Health Care Reform Articles - November 25, 2019 | 11/26/2019

… the health care industry in southwestern Pennsylvania is inescapable. Hospitals and clinics controlled by two competing health care behemoths, the University of Pittsburgh Medical Center and Highmark Blue Cross Blue Shield, dot Pittsburgh’s streets. The … government, and end the practice of large pharmaceutical companies like Novartis, United Health, Roche, Pfizer, and Merck vacuuming up senior government officials to try and monopolize government expertise, relationships, and influence during a fight for …

Aetna

2020 Insights on the Worldwide Pharma, Biotech and Diagnostics Manufacturing and Supply Partnering Terms and Agreements | Globe Newswire | 4/14/2020

… Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others. The report also … Aerial BioPharma Aerie Pharmaceuticals Aero Pump AEterna Zentaris Aethlon Medical Aetna Afaxys Pharmaceuticals Affymetrix Afinity Life Sciences AFT Pharmaceuticals AGC Biologics Agena Bioscience Agfa HealthCare Agilent Technologies Agile Therapeutics Agilis Biotherapeutics Agiomix FZ AgMedica Bioscience …

Humana

Government accepts millions of doses of drugs being studied as possible COVID-19 remedy | NBC News | 3/30/2020

… treatment for COVID-19. The Department of Health and Human Services said in a statement that Sandoz, a subsidiary of Novartis, donated 30 million doses of hydroxychloroquine sulfate, and Bayer Pharmaceuticals donated 1 million doses … health insurers waive coronavirus treatment costs Health insurers Cigna and Humana are now waiving patient cost-sharing on all treatment for coronavirus, including hospitalizations and ambulance transfers, for their insured members and employer plans. “Our …

Cigna

Government accepts millions of doses of drugs being studied as possible COVID-19 remedy | NBC News | 3/30/2020

… treatment for COVID-19. The Department of Health and Human Services said in a statement that Sandoz, a subsidiary of Novartis, donated 30 million doses of hydroxychloroquine sulfate, and Bayer Pharmaceuticals donated 1 million doses … Two large health insurers waive coronavirus treatment costs Health insurers Cigna and Humana are now waiving patient cost-sharing on all treatment for coronavirus, including hospitalizations and ambulance transfers, for their insured members and employer …

UnitedHealthcare

Five years on, biosimilars need support from all health care players - STAT | 3/6/2020

… McGowan March 6, 2020 The FDA approved Zarxio, the first U.S. biosimilar, on March 6, 2015. Sandoz, a division of Novartis T oday marks a milestone for the U.S. biosimilar market: the FDA approved our … care plans in the U.S. simultaneously advantage and disadvantage biosimilars. UnitedHealthcare , for example, has favored some biosimilars (like Pfizer’s Retacrit, Amgen’s Mvasi, and Amgen’s Kanjinti) over originator biologics for preferred status. In other therapeutic categories …

UPMC Health Plan

Pharma Isn’t Eager To Carry Cures Act 2.0 Over Finish Line Despite Being Instrumental In Passage Of First Version | Kaiser Health News | 12/4/2019

… be protected from generic imitators in the U.S.-Mexico-Canada Agreement, or USMCA. (Mauldin, Andrews and Leary, 12/2) Reuters: Pfizer, Novartis Lead $2 Billion Spending Spree On Gene Therapy Production Eleven drugmakers led by Pfizer … based on outcomes that patients report. In this instance, the UPMC Health Plan will pay less for two Biogen (BIIB) drugs — Tecfidera and Avonex — if patients say the medicines failed to help them, based on …

Oscar Health

Alignment Healthcare bucked the net loss trend among its peers’ financial performance | Business Insider | 11/20/2019

… over the same time frame last year, according to Business Insider Prime. BI Prime raked through the financial results of Oscar Health, Clover Health, Bright Health, Devoted Health, and Alignment Healthcare — which were the targets … benefits to the new healthcare technology Biofourmis teams up with Novartis to commercialize a digital therapeutics platform for heart failure patients A genetic testing firm launched an atrial fibrillation research app on Apple devices …

Harvard Pilgrim Health Care

Katerina Sudit Joins Hill Holliday’s Trilia as Chief Media Officer | Business Wire | 11/5/2019

… game-changing ideas for such industry leaders as Bank of America, Party City, Capella University, Optum, Boar’s Head, Simple Mobile, Novartis, Cracker Barrel, Bayer and Frontier Communications. For more about our people, our work, and … results. Trilia’s clients include Santander Bank, Tempur Sealy, Capella University, Harvard Pilgrim Health Care, Party City, Robert Half and Frontier Communications. For more about Trilia, please visit http://www.triliamedia.com . View source version on businesswire.com : https …

Molina Healthcare

Thursday, October 31, 2019 | Kaiser Health News | 10/31/2019

… year 2018. (Brady, 10/30) Modern Healthcare: Texas Awards Nearly $10 Billion In Medicaid Contracts Health insurers Anthem, Cigna Corp. and Molina Healthcare stand to lose millions in premium revenue after losing ground in the Texas … as more expensive brand-name drugs. (10/30) And in Reuters: Novartis’ Zolgensma Study Halted By FDA Amid Safety Questions U.S. regulators have halted a trial of Novartis’s Zolgensma treatment after an animal study raised safety …

Bright Health

NEA promotes two | PE Hub | 10/28/2019

… promotion to General Partner.” Mathers’ investments have led to numerous successful outcomes including Lumena (acquired by Shire), Ziarco (acquired by Novartis), and Motus Therapeutics (acquired by Allergan), among others. He currently serves on the boards … closely with many NEA portfolio companies including American Pathology Partners, Bright Health, Radiology Partners, and XOC Pharmaceuticals. Prior to joining NEA, he was a member of the private equity group at Ares Management. His earlier …

Clover Health

Dispensed: A trip to rural Pennsylvania, the final word on uBiome, and the looming cloud wars in healthcare | Markets Insider | Business Insider | 10/4/2019

Clover Health to develop new medications — seemingly an unorthodox choice. It’s not every day you see health insurers working with pharma companies. Why $45 billion pharma giant Roche is teaming up with a buzzy health-insurance startup to find new treatments for diseases Microsoft Microsoft vs. Google vs. Amazon Also — the cloud wars are heating up. The latest we’ve got our eye on is a deal between Microsoft and Novartis

Indian Health Service

Friday, August 30, 2019 | Kaiser Health News | 8/30/2019

… said in a speech before signing the 2009 measure into law. (Perrone, 8/29) Inspector General Report Keeps Pressure On Beleaguered Indian Health Services To Improve Quality Of Care The Indian Health Service has been beset … assessment, and biostatistics issues, among other things. (Silverman, 8/29) Reuters: Novartis Takes Aim At Roche’s Star MS Drug Swiss drugmaker Novartis on Friday stepped up its challenge to Roche’s multiple sclerosis franchise, highlighting study results …

Health Net

Novartis struggling to win payer coverage for $2.1M gene therapy Zolgensma: analysts | FiercePharma | 7/3/2019

Only about one-third of the top 30 U.S. insurance companies have made their decisions about how to cover Novartis’ new $2.1 million gene therapy to treat spinal muscular atrophy (SMA), Zolgensma, but analysts at … nine of the companies won’t allow concurrent treatment with Spinraza. Health Net is requiring any patient who’d used Spinraza to prove their disease progressed while on treatment before it will cover Zolgensma. Four of the …

SelectHealth

Novartis pitches discounts on pricey gene therapy for deadly muscle disorder - Nasdaq.com | 5/13/2019

Reuters By Deena Beasley and John Miller LOS ANGELES/ZURICH, May 10 (Reuters) - Novartis AG is offering price discounts in negotiations with U.S. health insurers on its gene therapy for spinal muscular atrophy (SMA), a … cost of therapy an important factor for them. Small insurer SelectHealth covers nearly 1 million people in Idaho and in Utah, where statewide newborn SMA testing began in 2018. SelectHealth said it has also pushed …

Anthem

U.S. STOCKS ON THE MOVE-iRobot, Snap, SAP, Novartis - Nasdaq.com | 4/24/2019

Reuters At 7:17 ET, Dow e-minis were up 0.15 percent at 26,680. S&P 500 e-minis were up 0.01 percent at 2,938.25, while Nasdaq 100 e-minis were up 0.02 percent at 7,839.25. The top three NYSE percentage gainers premarket : SAP SE , up 8.0 pct Novartis AG , up 3.4 pct Anthem Inc , up 2.7 pct The top NYSE percentage losers premarket : Bristow Group Inc , down 9.1 pct Occidental …

Centene Corp

AbbVie and Bristol-Myers Squibb will report first-quarter earnings on Thursday. Here’s what to expect - MarketWatch | 4/24/2019

Health-care earnings announcements are in full swing. Government insurance giant Centene Corp. reported on Tuesday morning, and Anthem Inc. , Biogen Inc. , Boston Scientific Corp. and Swiss drugmaker Novartis AG reported on Wednesday. Next up are AbbVie Inc. ABBV, +0.85% and Bristol-Myers Squibb Co. BMY, +2.29% Here’s what investors can expect on Thursday as these two pharmaceutical giants report first-quarter earnings. AbbVie, which is expected to report earnings …

Wellcare Health Plans

Health-care earnings: What to look out for on Tuesday and Wednesday - MarketWatch | 4/23/2019

… Government insurance giant Centene Corp. reported on Tuesday morning, and Anthem Inc., Biogen Inc., Boston Scientific Corp. and Swiss drugmaker Novartis AG are all reporting on Wednesday. The past week has been a difficult one … billion. The health insurer agreed last month to buy competitor WellCare Health Plans Inc. WCG, -0.75% for $15.3 billion, creating a managed-care giant in the business of government health programs and boosting Centene’s Medicare …

Wellcare

Health-care earnings: What to look out for on Tuesday and Wednesday - MarketWatch | 4/23/2019

… Government insurance giant Centene Corp. reported on Tuesday morning, and Anthem Inc., Biogen Inc., Boston Scientific Corp. and Swiss drugmaker Novartis AG are all reporting on Wednesday. The past week has been a difficult one … billion. The health insurer agreed last month to buy competitor WellCare Health Plans Inc. WCG, -0.75% for $15.3 billion, creating a managed-care giant in the business of government health programs and boosting Centene’s Medicare …

Richard Saynor

Edited Transcript of NOVN.VX earnings conference call or presentation 28-Apr-20 11:00am GMT | 5/2/2020

Q1 2020 Novartis AG Earnings Call Basel May 2, 2020 (Thomson StreetEvents) – Edited Transcript of Novartis AG earnings conference call or presentation Tuesday, April 28, 2020 at 11:00:00am GMT TEXT version of Transcript Corporate Participants Harry Kirsch Novartis AG - CFO John Tsai Novartis AG - Head of Global Drug Development & Chief Medical Officer Marie-France Tschudin Novartis AG - President of Novartis Pharmaceuticals Richard Saynor Novartis AG - CEO of Sandoz Samir Shah …

Susanne Schaffert

Edited Transcript of NOVN.VX earnings conference call or presentation 28-Apr-20 11:00am GMT | 5/2/2020

Q1 2020 Novartis AG Earnings Call Basel May 2, 2020 (Thomson StreetEvents) – Edited Transcript of Novartis AG earnings conference call or presentation Tuesday, April 28, 2020 at 11:00:00am GMT TEXT version of Transcript Corporate Participants … of Sandoz Samir Shah Novartis AG - Global Head of IR Susanne Schaffert Novartis AG - President of Novartis Oncology Vasant Narasimhan Novartis AG - CEO Conference Call Participants Emmanuel Douglas Papadakis Barclays Bank PLC, Research Division - MD …

Murdo Gordon

Amgen’s anti-inflammatory Otezla makes its foray into COVID-19 | 5/1/2020

… of anti-inflammatories that have entered clinical trials for the virus. They include Roche’s Actemra , Sanofi and Regeneron’s Kevzara and Novartis’ Ilaris . Cambrex Webinar Understanding the Importance of Crystallization Processes to Avoid Unnecessary Cost, Risk … Otezla right now because it is a convenient oral option,” Murdo Gordon, Amgen’s commercial chief, said during the call. “I think it’s the ideal kind of product at a time like this, where a lot …

Laura Wood

Inclisiran Drug Insights, 2020-2030: Clinical Trials, Markets, Competitors | 4/29/2020

… market competitors, and other emerging therapies. Overview Inclisiran, an investigational cholesterol-lowering treatment, was added to the pipeline from the Novartis acquisition of The Medicines Company. Inclisiran will potentially be the first and only LDL … focused, comprehensive and tailored research. Media Contact: Research and Markets Laura Wood , Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 …

Vas Narasimhan

Novartis’ cholesterol buster, new trial starts fall victim to pandemic: report | FierceBiotech | 4/28/2020

The COVID-19 pandemic has driven biopharmas left and right to hit pause on clinical trials, and Novartis is no exception. The Swiss pharma has stopped enrolling patients in a trial of its cholesterol fighter inclisiran even as it expects its trials to stay on course in the long term. “When you look across our clinical trials portfolio, we’re actually seeing very good performance,” Novartis CEO Vas Narasimhan, M.D., told …

Melinda Gates

Novartis maintains strong operational performance in Q1, confirms FY 2020 guidance at this time, and advances a broad range of efforts to support the global response to COVID-19 | Globe Newswire | 4/28/2020

… care for ill family members at home, enhanced child care, on-line learning programs and enabled working from home. Importantly, Novartis has made a commitment that there will be no COVID-19 related job losses … as the COVID-19 Therapeutics Accelerator, coordinated by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard, as well as a COVID-19 directed partnership organized by the Innovative Medicines Initiative. Both are cross-sector collaborations …

Donald Trump

How hydroxychloroquine toes the line between promise and ‘happy talk’ in the coronavirus fight | Yahoo News | 4/25/2020

… deeply involved in the war against the coronavirus, and is used to treat COVID-19 patients in controlled settings. President Donald Trump sparked a furor recently , when he floated hydroxychloroquine as a potential game-changer … prominent advocates involved in the fight against the pandemic. Recently, Novartis ( NVS ) CEO Vas Narasimhan told a German newspaper that pre-clinical data in animals and initial clinical studies show the drug actually kills the …

Anthony Fauci

Blood-pressure drugs are in the crosshairs of COVID-19 research | 4/23/2020

… categories that include Vasotec, Valsartan, Irbesartan, as well as their generic versions. In a recent interview with a medical journal, Anthony Fauci - the U.S. government’s top infectious disease expert - cited a report showing similarly high … beneficial because they block some of the hormone’s damaging effects. Novartis International AG and Sanofi SA are among the major drugmakers selling ACE inhibitors and ARBs. Sanofi spokesman Nicolas Kressmann said that patients should consult …

Eric Althoff

Novartis Kymriah® receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma | 4/22/2020

EAST HANOVER, N.J. , April 22, Novartis today announced that the US (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to Kymriah ® (tisagenlecleucel), for an investigational new indication to treat patients with relapsed or refractory (r … 26):2545–2554. Novartis Media Relations E-mail: [email protected] Eric Althoff Jamie Bennett Head, US Corp & Country External Comms, Director, US Media Relations Global Media & Corp Communications +1 862-217-3976 +1 646 438 4335 [email …

Baron Davis

‘LinkedIn for healthcare’ startup lands $13M backed by Menlo Ventures, Novartis | FierceHealthcare | 4/22/2020

Novartis DRX, Y Combinator, and Liquid 2 Ventures, a seed-stage fund led by former NFL quarterback Joe Montana. Other investors participating in the round included Baron Davis Enterprises, ClearPoint Investment, Jeff Hammerbacker and Underscore VC. H1 will use the capital to grow its existing team including sales, product designers, and engineering, as well as to fuel expansion into additional market segments. The New York City-based startup developed a …

David Li

Long-term outcomes of treat-and-extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results | 4/17/2020

… Novack, MD; Thomas G Chu, MD; Firas Rahhal, MD; Homayoun Tabandeh, MD; Richard H Roe, MD; Pouya N Dayani, MD; David Liao, MD; Alexander Walsh, MD; Daniel D Esmaili, MD. Contributors JP: Responsible for study … Kanghong, Clearside Biomedical, DORC, Eyepoint, Genentech/Roche, Iveric Bio, Kodiak, Novartis, ONL Therapeutics, Outlook Therapeutics, Oxurion, PolyPhotonics, Recens Medical, Regeneron, Regenxbio, Santen and Takeda. Received research grant funding from Adverum, Aerie Pharmaceuticals, Aerpio, Allergan, Apellis …

Brian Abrahams

Novartis, Amgen tout Aimovig’s benefits with real-world and long-term data | FiercePharma | 4/16/2020

Amgen and Novartis kicked off the new CGRP class of migraine prevention drugs with their 2018 approval for Aimovig, and their market-leading position is not one they want to cede. To back up their … for Emgality and 12.8% for Ajovy, RBC Capital Markets analyst Brian Abrahams wrote in a note to clients. As for sales, Aimovig generated $306 million in 2019, compared with $162 million for Emgality and $96 …

Arlene Weintraub

With Urogen’s Jelmyto nod, Big Pharma vet Liz Barrett preps for a virtual launch | 4/16/2020

With Urogen’s Jelmyto nod, Big Pharma vet Liz Barrett preps for a virtual launch by Arlene Weintraub Apr 16, 2020 11:36am Liz Barrett, who left Novartis to join UroGen as CEO last year, says the company is ready to commercialize its first product despite disruptions caused by the COVID-19 pandemic. (Novartis) Amid the COVID-19 pandemic and resulting quarantines, it would be easy to overlook an FDA approval of …

Nick Taylor

EuroBiotech Report—Witty joins WHO project, Arix cuts, Galapagos, Leo and Novartis | FierceBiotech | 4/16/2020

Novartis teamed up with cell therapy startup TScan Therapeutics. And more. — Nick Taylor 1. WHO tasks ex-GSK CEO Witty with hastening COVID-19 vaccine R&D The World Health Organization (WHO) has tasked ex-GlaxoSmithKline CEO Andrew Witty with helping accelerate development of a COVID-19 vaccine. Witty is taking a leave of absence from his job at UnitedHealth Group until around the end of the year to co …

Kyle Blankenship

Chutes & Ladders—Immunomedics taps Ipsen exec Semerjian as CEO | 4/10/2020

Kyle Blankenship , and we will feature it here at the end of each week. Immunomedics nabs new CEO as data revive hopes its troubled cancer drug can make the finish line Immunomedics Harout Semerjian will join as CEO. Semerjian, who comes from being Ipsen’s chief commercial officer and executive vice president and also served a major 16-year stint at Novartis Oncology, will now head up the biotech as it …

Paul Hudson

Sanofi offers 100 mln doses of hydroxychloroquine in COVID-19 fight | Yahoo News | 4/10/2020

Paul Hudson said in a statement, “If the trials prove positive, we hope our donation will play a critical role for patients.” Other companies have also pledged to offer the drugs, with Switzerland’s Novartis proposing 130 million doses of chloroquine, and Israeli generic producer Teva promising 10 million doses of HQC for US hospitals. Sanofi is also working on a potential vaccine for the new coronavirus, which has killed more …

Seema Verma

Trade group calls for government coverage of digital therapeutics amid pandemic | 4/8/2020

… The alliance includes 35 companies, some of which are startups and others of which are established pharmaceutical giants, such as Novartis and Bayer. advertisement The Digital Therapeutics Alliance is asking the federal health department to … In a letter to those senators in January, CMS Administrator Seema Verma wrote that the agency is “currently exploring ways” to let virtual providers get reimbursed for offering their services in the diabetes prevention program …

Angus Liu

COVID-19 is bad news for new drug launches. Which will suffer most? | 4/3/2020

COVID-19 is bad news for new drug launches. Which will suffer most? by Angus Liu Apr 3, 2020 12:19pm New drugs that treat non-life-threatening conditions or require significant educational efforts might suffer … circumstances. Also in the MS arena, a regulatory decision for Novartis’ repurposed ofatumumab might also come late, ODDO BHF analysts noted recently. Register for the On-Demand Webinar Rollouts from small-cap biotechs with little …

John Miller

Swiss Government Expands Powers to Force Firms to Make Supplies to Fight COVID-19 | U.S. News & World Report | 4/3/2020

… Novartis, Abbvie’s HIV drug Kaletra, Gilead Science’s experimental remdesivir and Roche’s Actemra, all of which are now being studied for potential use against coronavirus. Swissmedic also gets new powers to approve deviations from some legal requirements for drugs under review, the government said. (Reporting by John Miller; Editing by Michael Shields) Copyright 2020 Thomson Reuters …

Janet Woodcock

FDA Asks Sanofi to Pull Zantac From the Market, Citing Cancer Risk - TheStreet | 4/2/2020

… effort to investigate potential health risks and provide our recommendations to the public based on the best available science,” said Janet Woodcock director of the FDA’s Center for Drug Evaluation and Research. “We didn’t observe … Sanofi voluntarily recalled Zantac OTC in the U.S. and Canada. Novartis pulled its versions of ranitidine in September. The FDA also urged consumers to stop taking the drug. ADRs of Sanofi ( SNY ) - Get Report closed …

Mike Pence

Michael Hiltzik: Trump’s chloroquine obsession will harm millions - Los Angeles Times | LA Times | 4/1/2020

… Novartis, the lead manufacturer of the hydroxychloroquine formulation Herrera takes, Plaquenil, has donated 30 million doses of the drug to the federal government for stockpiling as a COVID-19 treatment. That raised the hackles of the Lupus Foundation and Arthritis Foundation, which have asked Vice President Mike Pence in a joint letter to ensure that their patients aren’t deprived of the medication. Meanwhile, doctors have been reported to be writing …

Alex Azar

Without data, but with Trump praise, FDA issues emergency nod for chloroquine in COVID-19 | FiercePharma | 3/30/2020

… their only other options are clinical trials. With the emergency authorization , the HHS has accepted 30 million donated doses from Novartis’ Sandoz unit. And with a similar nod for another form of the med—chloroquine … the evidence to evaluate which options are effective,” HHS Secretary Alex Azar said in a statement. The emergency approval follows routine praise for the drugs from President Donald Trump and preliminary study results out of …

Ben Adams

In conversation with: Science 37 and the response to COVID-19 | FierceBiotech | 3/27/2020

… near as often as traditional site-based studies. Siteless, decentralized studies were the future, and though the likes of Google, Novartis, Amgen, Sanofi and more have signed up to the idea, centralized tests remain “the … company, to assess its response to COVID-19’s challenges. Ben Adams: How are you managing the complexities of COVID-19 with your trials? Has it impacted/changed how you do your trials? Jonathan Cotliar …

Nancy Pelosi

Drug supplies, costs hurt by unintended consequences of COVID-19 policies, suppliers tell White House | FiercePharma | 3/27/2020

… under consideration by the White House would immediately raise prices for consumers who get their drugs through federal programs. RELATED: Novartis sidesteps Europe travel ban to provide CAR-T drug Kymriah to patients “As you … leader Charles Schumer as well as Speaker of the House Nancy Pelosi and House Republican leader Kevin McCarthy …

Mitch McConnell

Drug supplies, costs hurt by unintended consequences of COVID-19 policies, suppliers tell White House | FiercePharma | 3/27/2020

… under consideration by the White House would immediately raise prices for consumers who get their drugs through federal programs. RELATED: Novartis sidesteps Europe travel ban to provide CAR-T drug Kymriah to patients “As you … for the administration, it was sent to Senate Majority leader Mitch McConnell and Senate Democratic leader Charles Schumer as well as Speaker of the House Nancy Pelosi and House Republican leader Kevin McCarthy …